On Mar. 22, 2022, Novavax and Serum Institute of India announced that the Drugs Controller General of India (DCGI) had granted emergency use authorization (EUA) for Novavax’ protein-based COVID-19 vaccine for adolescents aged =12 to <18 years in India.

The vaccine, also known as NVX-CoV2373, is manufactured and marketed in India by SII under the brand name Covovaxﾙ and is the first protein-based vaccine authorized for use in this age group in India.